ALK-Abelló

Regulatory Filings • Nov 21, 2008

To NASDAQ OMX Copenhagen A/S

Translation

Company release No 20/2008

Hørsholm November 21, 2008

ALK achieves general reimbursement for GRAZAX® in Spain

Page 1/1 The Spanish authorities today announced that they have finalized the evaluation of ALK's application for price and reimbursement of the company's tablet based vaccine against grass pollen allergy with a positive outcome. GRAZAX® will now be eligible for general, national reimbursement on level with other pharmaceutical products in Spain. The decision, which comes earlier than anticipated, enables a launch of GRAZAX® for adults in Spain in due time ahead of the 2009 grass pollen season.

This announcement does not change ALK's financial outlook for 2008.

ALK-Abelló A/S

Jens Bager President & CEO

For further information please contact: Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525 Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. Our mission is to improve quality of life for allergic people by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. Our aim is to extend the use of allergy vaccination by introducing convenient, tablet-based vaccines, thereby offering many more patients a causal allergy treatment. Following this strategy, the world's first tablet-based vaccine against grass pollen allergy, GRAZAX® , was launched in Europe in 2007. ALK has entered into a strategic partnership regarding the tablet programme with Schering-Plough for North America. ALK has approximately 1,500 employees with subsidiaries, production facilities and distributors worldwide. The company is headquartered in Hørsholm, Denmark and listed on NASDAQ OMX Copenhagen A/S. 'ALK' is an abbreviation of 'Allergological Laboratory Copenhagen (København)'. Further information is available at www.alk-abello.com and www.GRAZAX® .com.